Redeye gives a short comment on the news that Eisai has lowered its forecast for its FY2024 (Q2-24-Q...
Redeye provides its initial comments on Nanologica's Q3 report, which showed softer-than-expected sa...
Q3 slightly slower than expected, partly due to discontinued product We cut '24e-'26e adj.
Operatively CapMan’s Q3 fell short of our expectations mainly due to negative fair value changes, wh...
Redeye provides an initial comment on the Q3 2024 report from Serstech.
We leave estimates relatively unchanged after Q3...
After the recent rights issue, Ascelia has SEK 95.
Redeye updates on G5 Entertainment post Q3-results which were weaker than expected.
Orders -9%, sales +10% vs. ABGSCe EBIT EUR 3m (vs. ABGSCe 2m), for a margin of 7% Profitability impr...
Sales -3%, EBITA +1% vs. ABGSCe, book-to-bill 0.99x Expects decline to decelerate from here, return ...
Redeye states that the Q3 report was solid, with ad revenues returning to y/y growth, while recurrin...
Redeye updated its forecast and valuation following the Q3 report, which showed strong ARR growth (i...
CapMan's Management company business turnover (excluding carried interest) grew 16% y/y in Q3, suppo...
Redeye provides a research update following Catella's Q3 2024 report.
Redeye provides an update following Optomed’s Q3 report.
We lower 2024E sales by ~4% and adjusted EBIT by 12%, driven by Germany, while we keep our estimates...
56% incre. EBITDA margin in Q3 highlights the scalability Increased confidence in positive EBIT in 2...
Nettoomsättningen för det tredje kvartalet uppgick till 0,93 MSEK (0,83), vilket var en ökning om 8,...
20% revenue beat driven by high watch sales, EBITDA 66% above Opex was above, but likely due to extr...
Resultatmässigt hade vi räknat med något lägre vinst än Q3 ifjol men minskningen var större än förvä...